CF
CAMP icon

Cantor Fitzgerald’s CAMP4 Therapeutics CAMP Stock Holding History

Cantor Fitzgerald’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,320
Closed -$17.9K – 401
2025
Q2 		$17.9K Buy
+12,320
New +$24.5K ﹤0.01% 409

Other funds holding CAMP

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cantor Fitzgerald's CAMP Position: Q3 2025 in Review

Cantor Fitzgerald sold out of CAMP4 Therapeutics (CAMP) in Q3 2025, closing a stake of 12,320 shares — an estimated $17.9K sold.

Cantor Fitzgerald first reported a position in CAMP in Q2 2025 and held it in 1 quarter. The position peaked at $17.9K in Q2 2025. 29 funds tracked by Wall St. Rank hold CAMP as of Q3 2025.

  • Cantor Fitzgerald reported no remaining CAMP4 Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 12,320 CAMP4 Therapeutics shares in Q3 2025, an estimated $17.9K.
  • Cantor Fitzgerald first reported a position in CAMP4 Therapeutics in Q2 2025 and held it in 1 quarter.
  • Cantor Fitzgerald's CAMP4 Therapeutics position peaked at $17.9K in Q2 2025.
  • 29 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2025.

Based on Cantor Fitzgerald's 13F filing for Q3 2025, filed 14 Nov 2025.